MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clgc.2022.11.004

Медицинская библиотека · Clinical genitourinary cancer · 2022

Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515).

Bastos Diogo A, Gongora Aline Bobato Lara, Dzik Carlos, Jardim Denis Leonardo, Piva Marina, Carcano Flavio Mavignier, Bertollo Glaucio, Trindade Karine, Fontes Mariane Sousa, Soares Andrey, Reinert Tomas, De Cassia Costamilan Rita, Villarroel Rodrigo Ughini, Watarai Gabriel, Gazola Antonia Angeli, Preto Daniel D Almeida, Mutti Haila, Bonalumi Dos Santos Marcela, Mariano Rodrigo Coutinho, Binotto Monique, Carvalho Monique Maciel, Oliveira Veronica Patrícia da Costa, Gomes Rafaela, Rebelatto Taiane F, Schutz Fabio A, Smaletz Oren, Fay Andre P

Многоцентровое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Germ-cell tumors (GCTs) are the most common malignancy in young men. There is a paucity of data on GCTs in developing countries. LACOG 0515 study aimed to evaluate clinical characteristics and treatment outcomes in patients with GCTs from Brazilian cancer centers.

MATERIALS AND

METHODS

This is a retrospective cohort study evaluating male patients diagnosed with GCTs from 2000 to 2018 in 13 Brazilian hospitals. We described baseline characteristics, progression-free survival (PFS), and overall survival (OS).

RESULTS

A total of 1232 patients were included, with a median age of 30 years. Histology was seminoma in 47.1% and non-seminoma GCT (NSGCT) in 52.9%. The primary tumor site was testis in 96.5%. At diagnosis, clinical stage I was present in 68.1% and 34.7% and clinical stages IS/II/III in 31.9% and 65.2% of patients with seminoma and NSCGT, respectively. Following orchiectomy, 55.2% of patients with clinical stage I were managed with surveillance. The 5-year disease-free survival rates among patients with stage I were 98.0% in seminoma and 92.3% in NSGCT, with 5-year OS of 99.6% and 97.6%, respectively. Among patients with advanced disease (IS, II, and III), the 5-year PFS were 88.7% in seminoma and 68.7% in NSGCT, with 5y-OS of 97.6% and 82.8%, respectively.

CONCLUSION

This is the largest Brazilian cohort of GCTs. Our results show a high rate of adjuvant chemotherapy in patients with clinical stage I. Although our data demonstrate slightly inferior PFS compared with the International Germ Cell Cancer Collaborative Group and other contemporary series, the OS rates were similar.

Для цитирования: Bastos Diogo A, Gongora Aline Bobato Lara, Dzik Carlos, Jardim Denis Leonardo, Piva Marina, Carcano Flavio Mavignier, Bertollo Glaucio, Trindade Karine, Fontes Mariane Sousa, Soares Andrey, Reinert Tomas, De Cassia Costamilan Rita, Villarroel Rodrigo Ughini, Watarai Gabriel, Gazola Antonia Angeli, Preto Daniel D Almeida, Mutti Haila, Bonalumi Dos Santos Marcela, Mariano Rodrigo Coutinho, Binotto Monique, Carvalho Monique Maciel, Oliveira Veronica Patrícia da Costa, Gomes Rafaela, Rebelatto Taiane F, Schutz Fabio A, Smaletz Oren, Fay Andre P. Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515).. Clinical genitourinary cancer. 2022. DOI: 10.1016/j.clgc.2022.11.004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.